Compare Freshworks Inc (FRSH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Repligen Corporation Common Stock — how do they compare? Freshworks Inc trades at $13.61 (market cap $3.62B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.1× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Repligen Corporation Common Stock for 0 Days on average.
| FRSH | RGEN | |
|---|---|---|
Market Cap | $3.62B | $11.14B |
Volume | 4,303,742 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $13.92 | $194.57 |
52-Week Low | $6.88 | $102.87 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.99B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.69, down 1.65% on the day, with a bullish technical signal and strong fundamental momentum. The company achieved GAAP profitability in Q2 2026, with revenue growth of 16% year-over-year and a net income margin of 20.49%. Analyst consensus is split evenly between Buy and Hold, with a price target of $14.60, suggesting modest upside from current levels. Recent news highlights AI adoption and enterprise growth as key drivers.
The outlook for FRSH is positive, supported by sustained revenue growth, improving profitability, and strategic focus on AI and employee experience products. Risks include competitive pressures in the SaaS sector and execution challenges in maintaining growth momentum. The stock presents an opportunity for investors seeking exposure to a profitable, growing software company with a reasonable valuation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
